Experimental gene therapy for DMD hits antibody barrier
NCT ID NCT06241950
First seen Nov 20, 2025 · Last updated May 22, 2026 · Updated 24 times
Summary
This study tested a gene therapy (delandistrogene moxeparvovec) combined with a drug called imlifidase to help patients with Duchenne muscular dystrophy who have antibodies that could block the therapy. Only 5 participants were planned, and the study was terminated early. The goal was to see if the treatment was safe and could produce dystrophin protein in muscle.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Sant Joan de Déu
Barcelona, 08950, Spain
Conditions
Explore the condition pages connected to this study.